Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL OILY versus LIPIODOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL OILY versus LIPIODOL.
DIONOSIL OILY vs LIPIODOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL OILY is a radiographic contrast agent containing propyliodone, which is an iodine-containing compound that absorbs X-rays, thereby enhancing the visualization of body structures during imaging procedures.
Lipiodol is an iodinated ethyl ester of the fatty acids of poppyseed oil. It acts as a radiopaque contrast agent for imaging due to its iodine content, and in chemoembolization, it selectively accumulates in hepatocellular carcinoma (HCC) via tumor neovasculature and is retained due to lack of lymphatic drainage, allowing targeted delivery of chemotherapeutic agents.
Adults: 10 mL intraurethral instillation as a sterile oily suspension (50% w/v) once daily for 3-5 days.
Lymphangiography: 5-20 mL injected slowly into lymphatic vessels. Uterine/Fallopian tube imaging: 3-20 mL injected through cervix. Hepatic chemoembolization: 5-15 mL mixed with chemotherapeutic agents injected into hepatic artery.
None Documented
None Documented
Terminal elimination half-life of the iodine moiety is approximately 60 days due to slow release from fatty tissues. This long half-life reflects the persistence of the oily vehicle and slow deiodination, necessitating monitoring for cumulative iodine effects.
Terminal elimination half-life is approximately 50-60 days, reflecting slow clearance from lipid-rich tissues.
Primarily renal excretion of the water-soluble metabolite (propiodone) after hepatic deiodination; approximately 60-80% of the administered iodine is excreted in urine within 48 hours. Fecal excretion is negligible (<5%).
Primarily eliminated via biliary/fecal route as unchanged drug; less than 1% excreted renally.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent